UNRESECTABLE CUTANEOUS MELANOMA
Clinical trials for UNRESECTABLE CUTANEOUS MELANOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE CUTANEOUS MELANOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE CUTANEOUS MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive drug targets Hard-to-Treat melanoma in early trial
Disease control Recruiting nowThis early-stage trial tests a radioactive drug called [225Ac]Ac-A9-3408 in 50 adults with melanoma that has spread or can't be removed by surgery. The main goals are to find a safe dose and check for side effects. Participants receive the drug every 6 weeks for up to 6 doses, an…
Matched conditions: UNRESECTABLE CUTANEOUS MELANOMA
Phase: PHASE1 • Sponsor: Alpha-9 Oncology USA Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Custom-Made vaccine trains immune system to fight advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …
Matched conditions: UNRESECTABLE CUTANEOUS MELANOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Morning vs. evening: can timing boost melanoma treatment?
Disease control Recruiting nowThis study tests whether giving standard immunotherapy drugs (ipilimumab and nivolumab) in the morning works better than giving them later in the day for people with advanced melanoma that has spread or cannot be removed. About 99 adults with stage IV melanoma will be randomly as…
Matched conditions: UNRESECTABLE CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Cancer patients may soon get immunotherapy at home instead of the clinic
Symptom relief Recruiting nowThis study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …
Matched conditions: UNRESECTABLE CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC